Skip to content
Subscriber Only

J&J to Pay $158 Million to Settle Texas Risperdal Drug Case

Johnson & Johnson agreed to pay $158 million to settle Texas officials’ claims that the drugmaker fraudulently marketed its Risperdal anti-psychotic drug, ending a trial over the allegations.

J&J’s settlement will resolve claims it defrauded the state’s Medicaid program by promoting Risperdal for uses not approved by U.S. regulators, including for children with psychiatric disorders, the company said today. The state also claimed the New Brunswick, New Jersey-based drugmaker downplayed the health risk of Risperdal. The settlement was about one-quarter of the $579 million the state was seeking.